Showing results (1-10 of 535) with videos related to
Sort By:
Pageof 54
BMC Pulmonary Medicine|May 20, 2026
Classification and regression trees to identify COPD subgroups in clinical trial populations: insights from the IMPACT trialLucile Regard, Jean-Louis Paillasseur, Pierre-Régis Burgel, et al.Expert Review of Respiratory Medicine|November 27, 2018
Acute and chronic non-pulmonary complications in adults with cystic fibrosisLucile Regard, Clémence Martin, Guillaume Chassagnon, et al.Chest|July 19, 2022
The Changing Epidemiology of Cystic Fibrosis: The Implications for Adult CarePierre-Régis Burgel, Espérie Burnet, Lucile Regard, et al.Seminars in Respiratory and Critical Care Medicine|December 19, 2022
CFTR Modulators: Current Status and Evolving KnowledgeLucile Regard, Clémence Martin, Jennifer Da Silva, et al.La Revue Du Praticien|March 29, 2024
[COPD: diagnostic and severity assessment]Lucile Regard, Nicolas RochePresse Medicale (Paris, France : 1983)|November 11, 2025
Difficult-to-treat COPD: from concept to practiceLucile Regard, Nicolas RocheInternational Journal of Chronic Obstructive Pulmonary Disease|August 25, 2021
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short ReviewClémence Martin, Pierre-Régis Burgel, Nicolas RocheMethods in Molecular Biology (Clifton, N.J.)|November 11, 2024
Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected LungsJean-Luc Teillaud, Lucile Regard, Clémence Martin, et al.Methods in Molecular Biology (Clifton, N.J.)|August 25, 2018
Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected LungsJean-Luc Teillaud, Lucile Regard, Clémence Martin, et al.Cells|June 10, 2022
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceLucile Regard, Clémence Martin, Espérie Burnet, et al.Pageof 54